-
-
- Health Management Policies Unit
- Health Economics and Financing Policies Unit
- Health Care Provision Policies Unit
- Health Workforce Policies Unit
- Health Industries Policies Unit
- Global Health Policies Unit
- Health Tourism Policies Unit
- Public Health Policies Unit
- R-D, Project, Education and Support Unit
-
-
-
- Contact
Last Added News
- The “Workshop on the Secure Collection and Sharing of Health Data,” Was Held in Collaboration Between TÜSEB and Istanbul Technical University (ITU)
- President and Scientific Board Members of the Türkiye Health Policies Institute Attended the ‘Neuron Platform Workshop’ Hosted by Istanbul University-Cerrahpaşa
- Policy Evaluation Report on Electronic Cigarettes and Novel Tobacco Products Has Been Published
- Türkiye Health Policies Institute Continues Its Work on Elderly Health
- The Second Meeting on Planning and Coordination of Vaccine Hesitancy Efforts Among the Units of the Ministry of Health of the Republic of Türkiye Was Held Online
- ALL NEWS
Research Results Announced at the Press Conference on “Türkiye’s First Economic Burden Study on RSV Infection”
The results of a scientific study revealing the economic burden of Respiratory Syncytial Virus (RSV) infection, which is commonly seen in infants in Türkiye, were shared with the public at a press conference held in Istanbul.
The launch meeting of this economic evaluation study in Türkiye featured presentations by Prof. Dr. Simten Malhan, Faculty Member at Başkent University Department of Healthcare Management and Project Director of the Center of Excellence in Good Clinical Practices, and Prof. Dr. Ateş Kara, President of the Türkiye Vaccine Institute and Faculty Member at Hacettepe University. The event was also attended by Prof. Dr. Işıl Maral, President of the Türkiye Health Policies Institute, and Prof. Dr. Haluk Özsarı, Member of the Scientific Board of the Türkiye Health Policies Institute.
The study examined the impact of RSV infection in children aged 0–5 years who were born between 2019 and 2023. According to the findings, the direct and indirect costs of treating more than 894,000 children infected with RSV were calculated to be 24.2 billion Turkish Lira. It was announced that 7 billion TL of this burden was covered by the Presidency of the Social Security Institution (SGK), while the remaining cost was borne by out-of-pocket expenses of parents and productivity losses due to workforce absence.
